Impact of Novel MiR-145-3p Regulatory Networks on Survival in Patients with Castration-resistant Prostate Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Jun 23

PMID 28641312

Citations 70

Authors

Yusuke Goto

Akira Kurozumi

Takayuki Arai

Nijiro Nohata

Satoko Kojima

Atsushi Okato

Mayuko Kato

Kazuto Yamazaki

Yasuo Ishida

Yukio Naya

Tomohiko Ichikawa

Naohiko Seki

Affiliations

Soon will be listed here.

Abstract

Background: Despite recent advancements, metastatic castration-resistant prostate cancer (CRPC) is not considered curative. Novel approaches for identification of therapeutic targets of CRPC are needed.

Methods: Next-generation sequencing revealed 945-1248 miRNAs from each lethal mCRPC sample. We constructed miRNA expression signatures of CRPC by comparing the expression of miRNAs between CRPC and normal prostate tissue or hormone-sensitive prostate cancer (HSPC). Genome-wide gene expression studies and in silico analyses were carried out to predict miRNA regulation and investigate the functional significance and clinical utility of the novel oncogenic pathways regulated by these miRNAs in prostate cancer (PCa).

Results: Based on the novel miRNA expression signature of CRPC, miR-145-5p and miR-145-3p were downregulated in CRPC. By focusing on miR-145-3p, which is a passenger strand and has not been well studied in previous reports, we showed that miR-145-3p targeted 4 key molecules, i.e., MELK, NCAPG, BUB1, and CDK1, in CPRC. These 4 genes significantly predicted survival in patients with PCa.

Conclusions: Small RNA sequencing for lethal CRPC and in silico analyses provided novel therapeutic targets for CRPC.

Citing Articles

Trillin inhibits MAP3K11/NF-κB/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer.

Wang Y, Peng Y, Hao W, He C, Gao X, Liang P iScience. 2025; 28(2):111505.

PMID: 39898047 PMC: 11787546. DOI: 10.1016/j.isci.2024.111505.

Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis.

Zhou Y, Yao W, Chen S, Wang P, Fu J, Zhao J Front Pharmacol. 2025; 15():1483186.

PMID: 39845793 PMC: 11753231. DOI: 10.3389/fphar.2024.1483186.

Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.

Rahman M, Ghorai S, Panda K, Santiago M, Aggarwal S, Wang T Noncoding RNA Res. 2024; 11:22-37.

PMID: 39736851 PMC: 11683234. DOI: 10.1016/j.ncrna.2024.11.001.

NCAPG-mediated CDK1 promotes malignant progression of non-small cell lung cancer via ERK signaling activation.

Wu Y, Yang M, Chen M, Tian L, Zhu Y, Chen L Am J Cancer Res. 2024; 14(11):5338-5350.

PMID: 39659935 PMC: 11626278. DOI: 10.62347/DNAQ7105.

BUB1 induces AKT/mTOR pathway activity to promote EMT induction in human small cell lung cancer.

Wang M, You L, Su Z, He Y, Li D, Liu Z Sci Rep. 2024; 14(1):20654.

PMID: 39232038 PMC: 11375037. DOI: 10.1038/s41598-024-71644-4.

References

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Aytes A, Mitrofanova A, Lefebvre C, Alvarez M, Castillo-Martin M, Zheng T . Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014; 25(5):638-651. PMC: 4051317. DOI: 10.1016/j.ccr.2014.03.017. View

Roubaud G, Liaw B, Oh W, Mulholland D . Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol. 2016; 14(5):269-283. PMC: 5567685. DOI: 10.1038/nrclinonc.2016.181. View

Elowe S . Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. Mol Cell Biol. 2011; 31(15):3085-93. PMC: 3147602. DOI: 10.1128/MCB.05326-11. View

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

Sachdeva M, Liu Q, Cao J, Lu Z, Mo Y . Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 2012; 40(14):6683-92. PMC: 3413133. DOI: 10.1093/nar/gks324. View

Catela Ivkovic T, Voss G, Cornella H, Ceder Y . microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett. 2017; 407:113-122. DOI: 10.1016/j.canlet.2017.04.007. View

10.

Chen S, Xu Y, Yuan X, Bubley G, Balk S . Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A. 2006; 103(43):15969-74. PMC: 1635111. DOI: 10.1073/pnas.0604193103. View

11.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

12.

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S . Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145. Int J Oncol. 2013; 42(4):1473-81. DOI: 10.3892/ijo.2013.1825. View

13.

Larne O, Hagman Z, Lilja H, Bjartell A, Edsjo A, Ceder Y . miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis. 2015; 36(8):858-66. DOI: 10.1093/carcin/bgv063. View

14.

Crawford E, Higano C, Shore N, Hussain M, Petrylak D . Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015; 194(6):1537-47. DOI: 10.1016/j.juro.2015.06.106. View

15.

Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, de Vries D . A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther. 2011; 10(10):1818-28. PMC: 3191241. DOI: 10.1158/1535-7163.MCT-11-0268. View

16.

Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

17.

Ganguly R, Hong C, Smith L, Kornblum H, Nakano I . Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther. 2014; 13(6):1393-8. PMC: 4048631. DOI: 10.1158/1535-7163.MCT-13-0764. View

18.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

19.

Baez-Vega P, Echevarria Vargas I, Valiyeva F, Encarnacion-Rosado J, Roman A, Flores J . Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget. 2016; 7(24):36321-36337. PMC: 5095003. DOI: 10.18632/oncotarget.9216. View

20.

Wang Y, Begley M, Li Q, Huang H, Lako A, Eck M . Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A. 2016; 113(35):9810-5. PMC: 5024598. DOI: 10.1073/pnas.1606862113. View